OIG supplement report
This article was originally published in The Tan Sheet
Office of the Inspector General draft report on effectiveness of dietary supplement claims, warnings for the elderly due out this summer, HHS division says; draft originally was expected by end of 2001. Report will be second supplement-related review conducted by OIG; office released findings on FDA's supplement adverse event reporting system roughly a year ago (1"The Tan Sheet" April 23, 2001, pp. 3-6)...
You may also be interested in...
The American Association of Poison Control Centers has received numerous dietary supplement adverse event reports that would be useful to FDA, an April 19 HHS Office of Inspector General report on dietary supplement AERs states.
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.